Concepedia

A. Johri

AJ

Statistics

Publications

15

Citations

649

H-Index

13

Active since

2004

Affiliations

Novartis (Switzerland)(Current)

Chinese University of Hong Kong

Memorial Sloan Kettering Cancer Center

Novartis (United States)

A. Johri is an author at Novartis (Switzerland) specializing in oncology, pharmacology, and chemotherapy.

Publications per year

2004–2019

15

Publications

15

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

Medicine, Oncology, Pharmacology +17

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

Arif Hussain, Robert S. DiPaola, Ari David Baron et al. · Annals of Oncology · 2008 · 51 citations · Full text

Medicine, Oncology, Urology +12

Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study

W.W. ten Bokkel Huinink, Jozef Šufliarský, Willem M. Smit et al. · Journal of Clinical Oncology · 2009 · 48 citations

Pharmacy, Oncology, Pharmacology +17

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders

Farhad Ravandi, Iphigenia L. Koumenis, A. Johri et al. · Haematologica · 2019 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer

Martin Förster, Stan B. Kaye, Amit M. Oza et al. · Clinical Cancer Research · 2007 · 31 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

1–5 of 15